Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG (10%) for Primary Immune Thrombocytopenia (ITP)
CTR20260366Phase 3Active
- Sponsor
- Hualan Biological Engineering Inc.
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of immune globulin in immune thrombocytopenia (ITP), sponsored by Hualan Biological Engineering Inc.. Started Feb 2026; status: active.
02
Drugs
immune globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20260366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260366.